Sullivan & Cromwell Guides Amgen on $415M DeCODE Buy
The Thousand Oaks, Calif.-based Amgen said the acquisition will help assist it in developing new genetics-based medicines that attack defective human genes. The deal doesn't require regulatory approval and is expected to close by the end of the year, the companies said.
Both companies portrayed the acquisition as being in...
To view the full article, register now.